Fors A, Forslund T, Sundström A, Wettermark B. Prescribing patterns of glucagon-like peptide-1 receptor agonists in the Swedish capital region—a register-based cross-sectional study. Eur J Clin Pharmacol. 2025;81(5):739–753. doi: 10.1007/s00228-025-03823-9.
Treciokiene I, Forslund T, Kahan T, Taxis K, Wettermark B. Have People Treated With Antihypertensives Been Diagnosed With Hypertension? A Cross-Sectional Study in Stockholm, Sweden. Pharmacoepidemiol Drug Saf. 2025;34(1):e70075. doi: 10.1002/pds.70075.
Wettermark B, Kalantaripour C, Forslund T, Hjemdahl P. Statin treatment for primary and secondary prevention in elderly patients—a cross-sectional study in Stockholm, Sweden. Eur J Clin Pharmacol. 2024. doi: 10.1007/s00228-024-03724-3
Komen JJ, Hunt NB, Pottegård A, Hjemdahl P, Wettermark B, Olesen M, Bennie M, Mueller T, Carragher R, Karlstad Ø, Kjerpeseth LJ, Klungel OH, Forslund T. Heterogeneity after harmonisation: A retrospective cohort study of bleeding and stroke risk after the introduction of direct oral anticoagulants in four Western European countries. Pharmacoepidemiol Drug Saf. 2023;32:1223-1232.
Komen JJ, Pottegård A, Mantel-Teeuwisse AK, Forslund T, Hjemdahl P, Wettermark B, Hallas J, Olesen M, Bennie M, Mueller T, Carragher R, Karlstad Ø, Kjerpeseth LJ, Klungel OH. Oral anticoagulants in patients with atrial fibrillation at low stroke risk: a multicentre observational study. Eur Heart J. 2022;43:3528-3538.
Forslund T, Braunschweig F, Holzmann MJ, Siddiqui AJ. Early Risk of Stroke in Patients Undergoing Acute Versus Elective Cardioversion for Atrial Fibrillation. J Am Heart Assoc. 2021. doi: 10.1161/JAHA.121.021716
Komen J, Pottegård A, Hjemdahl P, Mantel-Teeuwisse AK, Wettermark B, Hellfritzsch M, Hallas J, Herings R, Smits L, Forslund T, Klungel O. Non-vitamin K antagonist oral anticoagulants, proton pump inhibitors and gastrointestinal bleeds. Heart. 2021. doi: 10.1136/heartjnl-2021-319332
Komen JJ, Pottegård A, Mantel-Teeuwisse AK, Forslund T, Hjemdahl P, Wettermark B, Hellfritzsch M, Hallas J, Olesen M, Bennie M, Mueller T, Voss A, Schink T, Haug U, Kollhorst B, Karlstad Ø, Kjerpeseth LJ, Klungel OH. Persistence and adherence to non-vitamin K antagonist oral anticoagulant treatment in patients with atrial fibrillation across five Western European countries. Europace. 2021. doi: 10.1093/europace/euab091
Komen JJ, Belitser SV, Wyss R, Schneeweiss S, Taams AC, Pajouheshnia R, Forslund T, Klungel OH. Greedy caliper propensity score matching can yield variable estimates of the treatment-outcome association—A simulation study. Pharmacoepidemiol Drug Saf. 2021;30:934-951. doi: 10.1002/pds.5232
Forslund T, Carlsson AC, Ljunggren G, Ärnlöv J, Wachtler C. Patterns of multimorbidity and pharmacotherapy: a total population cross-sectional study. Fam Pract. 2020:cmaa056. doi: 10.1093/fampra/cmaa056
Forslund T, Kosidou K, Wicks S, Dalman C. Trends in psychiatric diagnoses, medications and psychological therapies in a large Swedish region: a population-based study. BMC Psychiatry. 2020;20:328.
Komen JJ, Heerdink ER, Klungel OH, Mantel-Teeuwisse AK, Forslund T, Wettermark B, Hjemdahl P. Long-term persistence and adherence with non-vitamin K oral anticoagulants in patients with atrial fibrillation and their associations with stroke risk. Eur Heart J Cardiovasc Pharmacother. 2020. doi: 10.1093/ehjcvp/pvaa017
Komen JJ, Forslund T, Mantel-Teeuwisse AK, Klungel OH, von Euler M, Braunschweig F, Wallén H, Hjemdahl P. Association of Preceding Antithrombotic Therapy in Atrial Fibrillation Patients with Ischemic Stroke, Intracranial Hemorrhage, or Gastrointestinal Bleed and Mortality. Eur Heart J Cardiovasc Pharmacother. 2019. doi: 10.1093/ehjcvp/pvz063
Wändell P, Forslund T, Danin Mankowitz H, Ugarph-Morawski A, Eliasson S, Braunschweig F, Holmström M. Venous thromboembolism 2011–2018 in Stockholm: a demographic study. J Thromb Thrombolysis. 2019;48:668-673.
Forslund T, Wettermark B. Primärvårdens roll i sjukvårdssystemet. Hälso- och sjukvårdsförvaltningen, Region Stockholm, 2019.
Komen J, Hjemdahl P, Mantel-Teeuwisse AK, Klungel OH, Wettermark B, Forslund T. Concomitant anticoagulant and antidepressant therapy in atrial fibrillation patients and risk of stroke and bleeding. Clin Pharmacol Ther. 2019. doi: 10.1002/cpt.1603
Hjemdahl P, Braunschweig F, Holmström M, Johnsson H, von Euler M, Wallén H, Forslund T. Förbättrad strokeprevention vid förmaksflimmer med NOAK. Erfarenheter från Stockholms Län. Läkartidningen. 2018;115:FAH6.
Forslund T, Roos F, Wettermark B. Tillgänglighet i primärvården. Till vem, för vad och på vilket sätt? Hälso- och sjukvårdsförvaltningen, Stockholms Läns Landsting, 2018.
Forslund T, Komen J, Andersen M, Wettermark B, von Euler M, Mantel-Teeuwisse AK, Braunschweig F, Hjemdahl P. Improved stroke prevention in atrial fibrillation after the introduction of NOACs – the Stockholm experience. Stroke. 2018;49:2122–2128.
Forslund T, Wettermark B, Andersen M, Hjemdahl P. Stroke and bleeding with NOAC or warfarin treatment in patients with non-valvular atrial fibrillation: a population based cohort study. Europace. 2018;20:420–428.
Loikas D, Forslund T, Wettermark B, Schenk-Gustafsson K, Hjemdahl P, von Euler M. Sex and Gender Differences in Thromboprophylactic Treatment of Patients with Atrial Fibrillation After the Introduction of Non-Vitamin K Oral Anticoagulants. Am J Cardiol. 2017;120:1302–1308.
Komen J, Forslund T, Hjemdahl P, Wettermark B. Factors associated with antithrombotic treatment decisions for stroke prevention in atrial fibrillation in the Stockholm region after the introduction of NOACs. Eur J Clin Pharmacol. 2017;73:1315–1322.
Komen J, Forslund T, Hjemdahl P, Andersen M, Wettermark B. Effects of policy interventions on the introduction of novel oral anticoagulants in Stockholm: an interrupted time series analysis. Br J Clin Pharmacol. 2017;83:642–652.
Forslund T, Wettermark B, Hjemdahl P. Comparison of treatment persistence with different oral anticoagulants in patients with atrial fibrillation. Eur J Clin Pharmacol. 2016;72:329–338.
Forslund T, von Euler M, Johnsson H, Holmström M, Wettermark B, Hjemdahl P. Fler med förmaksflimmer får antikoagulantia sedan NOAK kom. Läkartidningen. 2015;112:CZYS.
Forslund T, Wettermark B, Wändell P, von Euler M, Hasselström J, Hjemdahl P. Risks for stroke and bleeding with warfarin or aspirin treatment in patients with atrial fibrillation at different CHA₂DS₂-VASc scores. Eur J Clin Pharmacol. 2014;70:1477–1485.
Forslund T, Wettermark B, Wandell P, von Euler M, Hasselström J, Hjemdahl P. Risk scoring and thromboprophylactic treatment of patients with atrial fibrillation with and without access to primary healthcare data. Int J Cardiol. 2013;170:208–214.
Forslund T, Raaschou P, Hjemdahl P, Krakau I, Wettermark B. Usage, Risk and Benefit of Weight-Loss Drugs in Primary Care. J Obes. 2011;2011:459263.
Forslund T, Raaschou P, Hjemdahl P, Krakau I, Wettermark B. Bantningsläkemedel tycks inte göra någon nytta. Läkartidningen. 2010;107:910–913.
Forslund T. 100 % hälsa på jobbet. Redaktionen, 2006.
Forslund T. Technology Transfer in Europe – Comparing Five Regions. Karolinska Institutet, 2002.
